Share on StockTwits
 

Smith & Nephew (LON:SN)‘s stock had its “buy” rating reaffirmed by equities researchers at Galvan Research in a research report issued on Thursday, Analyst Ratings Network reports. They currently have a GBX 920 ($15.17) price objective on the stock. Galvan Research’s price objective points to a potential upside of 6.85% from the company’s current price.

SN has been the subject of a number of other recent research reports. Analysts at BNP Paribas reiterated an “outperform” rating on shares of Smith & Nephew in a research note to investors on Friday, December 6th. They now have a GBX 950 ($15.66) price target on the stock. Separately, analysts at Morgan Stanley upgraded shares of Smith & Nephew to an “overweight” rating in a research note to investors on Tuesday, December 3rd. Finally, analysts at Numis Securities Ltd reiterated an “add” rating on shares of Smith & Nephew in a research note to investors on Monday, December 2nd. They now have a GBX 870 ($14.34) price target on the stock. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating and five have issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of GBX 814.07 ($13.42).

Smith & Nephew (LON:SN) opened at 860.9999 on Thursday. Smith & Nephew has a one year low of GBX 677.50 and a one year high of GBX 875.50. The stock’s 50-day moving average is GBX 832.8 and its 200-day moving average is GBX 790.4. The company’s market cap is £7.740 billion.

Smith & Nephew plc is a global medical devices business operating in the markets for orthopaedic reconstruction and trauma, endoscopy (LON:SN) and advanced wound management.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.